PMID- 32712868
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2629-3277 (Electronic)
IS  - 2629-3277 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Aug
TI  - Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived 
      from Human Induced Pluripotent Stem Cells.
PG  - 792-808
LID - 10.1007/s12015-020-09990-9 [doi]
AB  - Mesenchymal stem cells (MSC) are an important type of cell that are highly 
      recognized for their safety and efficacy as a cell therapy agent. In order to 
      obtain MSC, primary tissues (adipose tissue, bone marrow, and umbilical cord 
      blood) must be used; however, these tissues, especially umbilical cord blood, are 
      difficult to obtain due to various reasons, such as the low birth rate trend. In 
      addition, to maximize the safety and efficacy of MSC as allogenic cell 
      therapeutic agents, it is desirable to minimize the possibility of an immune 
      rejection reaction after in vivo transplantation. This study tried to establish a 
      novel method for producing induced pluripotent stem cells (iPSC)-derived MSC in 
      which the human leukocyte antigen (HLA)-class I gene is knocked out. To do so, 
      dermal fibroblast originated iPSC generation using Yamanaka 4-factor, HLA class I 
      gene edited iPSC generation using CRISPR/Cas9, and differentiation from iPSC to 
      MSC using MSC culture medium was utilized. Through this, HLA-A, B, and C 
      pseudo-homozygous iPSC-derived MSC (KO iMSC) were produced by monoallelically 
      knocking out the polymorphic HLA-A, B, and C genes, which are the major causes of 
      immune rejection during allogenic cell transplantation. Produced KO iMSC 
      possesses multipotency and it was safe in vivo to be able to be differentiated to 
      cartilage. In addition, it was not attacked by natural killer cells unlike HLA 
      class I null cells. In conclusion, KO iMSC that do not induce immune rejection 
      during allogenic cell transplantation can be produced. In the future, KO iMSC can 
      be successfully utilized as allogenic cell therapeutic agents for many recipients 
      through HLA screening.
FAU - Kwon, Daekee
AU  - Kwon D
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Ahn, Hee-Jin
AU  - Ahn HJ
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Han, Mi-Jung
AU  - Han MJ
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Ji, Minjun
AU  - Ji M
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Ahn, Jongchan
AU  - Ahn J
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Seo, Kwang-Won
AU  - Seo KW
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea.
FAU - Kang, Kyung-Sun
AU  - Kang KS
AUID- ORCID: 0000-0002-9322-741X
AD  - Stem Cells and Regenerative Bioengineering Institute in Kangstem Biotech, 
      Biomedical Science Building, #81 Seoul National University, Seoul, 08826, South 
      Korea. kangpub@snu.ac.kr.
AD  - Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National 
      University, Seoul, 08826, South Korea. kangpub@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Cell Differentiation
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Homozygote
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology
MH  - Mesenchymal Stem Cells/*cytology
MH  - Mice, Inbred BALB C
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Models, Biological
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Gene knockout
OT  - Human leukocyte antigen
OT  - Induced pluripotent stem cells
OT  - Mesenchymal stem cells
EDAT- 2020/07/28 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/07/27 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/07/27 06:00 [entrez]
AID - 10.1007/s12015-020-09990-9 [pii]
AID - 10.1007/s12015-020-09990-9 [doi]
PST - ppublish
SO  - Stem Cell Rev Rep. 2020 Aug;16(4):792-808. doi: 10.1007/s12015-020-09990-9.